Liraglutide - Placebo

DRUG2 trials

Sponsors

Leiden University Medical Center

Conditions

Cardiovascular DiseaseDiabetes Mellitus Type 2Diastolic DysfunctionFatty LiverMetabolic Syndrome

Phase 4

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

CompletedNCT01761318

Leiden University Medical CenterCardiovascular Disease, Diabetes Mellitus Type 2, Diastolic Dysfunction +2

Start: 2013-11-30End: 2016-03-31Updated: 2016-05-05

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

CompletedNCT02660047

Leiden University Medical CenterCardiovascular Disease, Diabetes Mellitus Type 2, Diastolic Dysfunction +2

Start: 2015-08-31End: 2018-03-09Updated: 2018-03-21

Related Papers

Circulating FGF21 is lower in South Asians compared with Europids with type 2 diabetes mellitus

Endocrine Connections2024-12-061 citations

Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.

2019-12-1339 citations

Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation

Diabetologia2019-11-05112 citations

Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort

Scientific Reports2019-07-106 citations

A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients

Cardiovascular Diabetology2019-07-0982 citations

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.

2019-04-30102 citations